• Publications
  • Influence
Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS
XP13512 1,200 mg, taken once daily, significantly improved restless legs syndrome (RLS) symptoms compared with placebo and was generally well tolerated in adults with moderate to severe primary RLS.
Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin
XP13512 may provide more predictable gabapentin exposure and decreased dosing frequency because it is a novel transported prodrug of gABapentin that is absorbed throughout the entire length of the intestine by high‐capacity nutrient transporters.
Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media.
MEF amoxicillin penetration tended to be lower in children with viral infection, which is inadequate to effectively eradicate resistant Streptococcus pneumoniae, particularly during viral coinfection.
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.
GEn was effective in providing PHN pain relief, improved gabapentin exposure compared with gabAPentin capsules, and was generally safe and well tolerated in patients with PHN.
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials
Although these analyses were potentially limited by the use of clinical trial data and not prospective data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS symptoms.
Effect of pH on disintegration and dissolution of ketoconazole tablets.
In the buffer solutions tested, dissolution but not disintegration of ketoconazole tablets is pH-dependent, and the characteristics of 200- and 400-mg doses of ketconazole are similar at pH 3.5.
Azathioprine Metabolism: Pharmacokinetics of 6‐Mercaptopurine, 6‐Thiouric Acid and 6‐Thioguanine Nucleotides in Renal Transplant Patients
The persistence of TGN in body tissues thus provides a pharmacokinetic rationale for the conventional once or twice daily AZA regimen, and the long elimination t1/2 may also predispose patients to excessive accumulation of the active metabolite and gradual development of T GN‐induced myelosuppression.